Target intelligence / Profile preview

Brain and muscle ARNT-like protein 1 (BMAL1) (BMAL1)

Target
BMAL1
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein, PAS domain-containing protein
01

Overview

Brain and muscle ARNT-like protein 1 (BMAL1), encoded by the ARNTL gene, is a master transcription factor and a core component of the mammalian circadian clock (UniProt: P49759). It functions by forming a heterodimer with CLOCK or NPAS2, which binds to E-box sequences in the promoter regions of clock-controlled genes to initiate their transcription (PubMed: 24037396). This molecular oscillator regulates a wide array of physiological processes, including glucose metabolism, lipid homeostasis, and immune responses. Dysregulation of BMAL1 is strongly associated with metabolic disorders, such as obesity and type 2 diabetes, as well as accelerated aging and various forms of cancer (PubMed: 30635457). In the context of pharmacology, BMAL1 is an emerging therapeutic target; small molecules like the natural flavonoid Nobiletin have been shown to enhance its activity, offering potential treatments for metabolic and neurodegenerative diseases (PubMed: 27090315). Additionally, the BMAL1-dependent clock machinery is being explored in chronotherapy to optimize the timing of drug delivery and minimize toxicity (PubMed: 29107506).

Other names
ARNTLMOP3BHLHE5PASD3Member of PAS protein 3Basic helix-loop-helix-PAS protein MOP3
02

Mechanism of action

BMAL1 functions by forming a heterodimer with CLOCK or NPAS2 to bind E-box elements (5'-CACGTG-3') in the promoters of clock-controlled genes, thereby driving the rhythmic expression of the molecular clock's primary and secondary feedback loops (PubMed: 24037396).

03

Biological functions

Circadian rhythm regulationMetabolic homeostasisCell cycle controlDNA damage responseImmune response regulation
04

Disease associations

Metabolic syndromeType 2 diabetesSleep-wake disordersCancerCardiovascular diseaseNeurodegenerative disease
05

Safety considerations

Circadian rhythm disruptionPotential for metabolic dysregulationAlteration of sleep-wake cyclesChronotoxicity of co-administered drugs
06

Interacting drugs

Nobiletin

4 more in the full profile.

07

Biomarkers

BMAL1 mRNA expression levelsBMAL1 protein rhythmicityPeriod 2 (PER2) expressionCircadian phase markers (e.g., dim light melatonin onset)

Beyond the preview

Go deeper on Brain and muscle ARNT-like protein 1 (BMAL1) (BMAL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brain and muscle ARNT-like protein 1 (BMAL1) (BMAL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call